ArticleDiscover oncology2025
Construction of an immune prediction model for osteosarcoma based on coagulation-related genes.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe prognostic outcome of osteosarcoma, as the most common primary malignancy in children and adolescents, has not improved with the development of modern medical care, and the aim of this study was to investigate the role of the coagulation system in the diagnosis and development of osteosarcoma.
methodsTRGET and GEO databases were used to acquire clinical information and matching RNA data from osteosarcoma patients. To find novel molecular groupings based on coagulation systems, shared clustering was used. TIMER, SSGSEA, CIBERSORT, QUANTISEQ, XCELL, EPIC, and MCPCOUNTER analyses were used to identify the immunological status of the identified subgroups and tumor immune microenvironment (TIME). To understand the underlying processes, functional studies such as GO, KEGG, and protein-protein interaction (PPI) network analysis were used. Prognostic risk models were built using the LASSO technique and multivariate Cox regression analysis.
resultsThe two molecular subgroups exhibited significantly different overall survival outcomes. Patients in one group demonstrated markedly better survival, suggesting the prognostic relevance of the molecular classification. This favorable prognosis was linked to a more active anti-tumor immune microenvironment, characterized by higher immune scores, lower tumor purity, and increased immune cell infiltration. Differential gene expression analysis between the two subgroups revealed a strong enrichment in immune-related and extracellular matrix (ECM)-associated pathways, as shown by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. These findings suggest that both immune activity and ECM remodeling may contribute to the prognostic differences between subgroups. Furthermore, a prognostic risk model constructed using coagulation system-related genes (CRGs) demonstrated solid predictive ability for patient survival. Patients classified into high- and low-risk groups by this model also exhibited distinct survival curves. Finally, we developed a nomogram by integrating the CRG-based risk score with key clinical variables. This nomogram showed good predictive performance and could serve as a clinically applicable tool for estimating survival in patients with osteosarcoma.
conclusionIn patients with osteosarcoma, the expression of genes associated to the coagulation system is strongly related to the immunological milieu and can be utilized to correctly predict the prognosis of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.